Join the Oncology Voice Network. Join for Free
How to Negotiate a Job Offer
negotiate a job offer job offer negotiation tips responding to job offers understanding job market job compensation disclosure

How to Negotiate a Job Offer


Share This Article


Summary

I have a special episode today by request. I’m going to talk about how to negotiate a job offer. I’m sincerely hoping that there's a lot of you out there that’s in this position or very soon will be and you’ll find this information really useful.

In this episode:

  • Few questions to ask yourself when you get close to job offer
  • Be gracious and react positively
  • Be tactful
  • Be responsive
  • Know the market
  • Know your “why”
  • Don’t over negotiate
  • Should we always try to negotiate and never accept the initial offer
  • Should we disclose our current compensation
  • When (and when not) do we disclose our compensation
  • How do companies put together/determine a job offer
  • How and when do companies offer sign-in bonuses

Click for Source
negotiate a job offer, job offer negotiation tips, responding to job offers, understanding job market, job compensation disclosure

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Podcast
COMP: How HR Determines Compensation and Titles for Job Offers
Partner Avatar MSL Talk: Tom Caravela, Chris Castin

COMP: How HR Determines Compensation and Titles for Job Offers

Article
Confounding factors in exposure–response analyses and mitigation strategies for monoclonal antibodies in oncology
OVN Avatar Sonoko Kawakatsu, René Bruno, Matts Kågedal, Chunze Li, Sandhya Girish, Amita Joshi, Benjamin Wu

Confounding factors in exposure–response analyses and mitigation strategies for monoclonal antibodies in oncology

Article
Level of evidence used in recommendations by the National Comprehensive Cancer Network (NCCN) guidelines beyond Food and Drug Administration approvals
OVN Avatar R. Kurzrock, L.A. Gurski, R.W. Carlson, D.S. Ettinger, S.M. Horwitz, S.K. Kumar, L. Million, M. von Mehren, A.B. Benson III

Level of evidence used in recommendations by the National Comprehensive Cancer Network (NCCN) guidelines beyond Food and Drug Administration approvals

Article
EHA evaluation of the ESMO-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for hematological malignancies
OVN Avatar Barbara Kiesewetter , Nathan I Cherny, Nicolas Boissel, Francesco Cerisoli, Urania Dafni, Elisabeth G E de Vries, Paolo Ghia, Nicola Gökbuget, Verónica González-Calle, Brian Huntly, Ulrich Jäger, Nicola Jane Latino, Jean-Yves Douillard, Luca Malcovati, Ma

EHA evaluation of the ESMO-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for hematological malignancies

Article
The First 2 Years of Biosimilar Epoetin for Cancer and Chemotherapy-Induced Anemia in the U.S.: A Review from the Southern Network on Adverse Reactions
OVN Avatar Charles L. Bennett , Sumimasa Nagai , Andrew C. Bennett , Shamia Hoque , Chadi Nabhan , Martin W. Schoen , William J. Hrushesky , Stefano Luminari , Paul Ray , Paul R. Yarnold , Bart Witherspoon , Josh Riente , Laura Bobolts , John Brusk , Rebecca Tombles

The First 2 Years of Biosimilar Epoetin for Cancer and Chemotherapy-Induced Anemia in the U.S.: A Review from the Southern Network on Adverse Reactions

Article
Large pharma companies reduced headcounts by more than 22K in 2025 as $300B patent cliff looms
OVN Avatar Angus Liu

Large pharma companies reduced headcounts by more than 22K in 2025 as $300B patent cliff looms

Explore OVN